News

Find out about our current activities

Click on the news below to find out more about our current activities and media coverage.

InSphero Launches 3D InSight™ Monkey Liver Microtissues at Annual Society of Toxicology Meeting

InSphero Launches 3D InSight™ Monkey Liver Microtissues at Annual Society of Toxicology Meeting

3D liver microtissues comprised of cynomolgus hepatocytes provide physiologically relevant in vitro model for investigating species-specific liver toxicity. PDF Version

Schlieren, Switzerland - March 16, 2017 – InSphero AG, the leading supplier of advanced, yet easy-to-use 3D cell culture-based solutions for drug discovery and development, today announced the launch of 3D InSight™ Monkey Liver Microtissues, further expanding the company’s suite of organotypic 3D liver models for in vitro safety and efficacy testing. Data describing the model’s characterization and application as an alternative to drug testing in animals was presented on Wednesday at the Society of Toxicology’s 56th Annual Meeting and ToxExpo in Baltimore, Maryland.

Drug-induced liver injury (DILI) remains one of the most common causes of late-stage failure in drug development and post-market drug withdrawal. Testing in non-human primates is often required to assess toxicity and potential liver-related side-effects prior to Phase I clinical trials in human patients. 3D InSight™ Monkey Liver Microtissues are a 3D spheroid liver model comprised of primary cynomolgus hepatocytes that serve as an in vitro alternative to in vivo animal tests, enabling testing species-specific effects of a drug on liver function and toxicity in preclinical studies. Viable for more than 28 days in culture, Monkey Liver Microtissues allow long-term drug exposure for predicting DILI and identifying potential mechanisms of toxicity.

InSphero Chief Scientific Officer Dr. Patrick Guye says, “Our 3D monkey liver model addresses the growing trend to reduce or replace the use of animal models in safety testing with more biologically relevant in vitro cell based models. When studies in non-human primates are still required, pre-testing in vitro can help safety and investigative toxicology groups to more effectively plan and minimize the use of costly and ethically charged animal testing. When combined with our human, rat, and dog liver models, our 3D monkey liver microtissues provide toxicologists a more complete toolbox of highly predictive human and animal-derived liver models for in vitro safety testing.”

For more information about InSphero, visit www.insphero.com.

 

InSphero contacts

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Patrick Guye
Chief Scientific Officer
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of organotypic 3D cell culture models. The company’s patented technologies include the 3D Select™ Process (pending) and scaffold-free 3D cell culture plates that enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, and tumors. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictive power at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and and LinkedIn, and visit www.insphero.com.

 

Image

InSphero monkey liver microtissue histology

InSphero 3D InSight™ Monkey Liver Microtissues serve as an in vitro alternative to pre-clinical animal testing for assessment of drug effects on liver function and toxicity. 

InSphero to Introduce GravityTRAP™ 384 Microtissue Platform at SLAS2017

InSphero to Introduce GravityTRAP™ 384 Microtissue Platform at SLAS2017

Global leader in 3D cell culture technology to deliver standardized 3D models in new high-throughput, high-content-imaging-optimized format. PDF Version

Schlieren, Switzerland - February 2, 2017 – InSphero AG, the leading supplier of advanced, yet easy-to-use 3D cell culture-based solutions for drug discovery and development, will debut the GravityTRAP™ 384 Microtissue Platform at the Society for Laboratory Automation and Screening (SLAS) 2017 Conference, February 4-8, in Washington, D.C.

Engineered specifically for 3D microtissue culture, the GravityTRAP™ 384 platform includes two features that differentiate it from existing 384-well plates: distinct microtissue culture and media chambers separated by a tapered SureXchange™ pipetting ledge, providing safe medium aspiration and exchange without accidental loss of microtissues; and a continuous flat-bottomed glass base plate combined with a black-walled body, ensuring superior confocal and high content imaging optics while reducing fluorescent cross-talk between wells. The platform conforms to Society for Biomolecular Screening (SBS) standards and is compatible with state-of-the-art high content imaging and automated liquid handling systems.

“More and more, industry is looking to leverage 3D models that better reflect in vivo biology at earlier stages in drug discovery and development, such as target validation and efficacy screens for potency and selectivity,” said Dr. Jan Lichtenberg, InSphero Chief Executive Officer and Co-founder. “However, the current generation of 384-well plates can cause production inconsistencies, complicate handling steps, and decrease the quality and reproducibility of data obtained. These are all critical factors that impact R&D groups overseeing high-throughput screening (HTS) workflows. The GravityTRAP™ 384 Microtissue Platform addresses these issues, providing a plug-and-play solution for HTS. Our customers will receive 384 of our fully qualified, assay-ready 3D InSight™ Microtissues in a plate that is designed for high-content optics and eliminates accidental loss of microtissues during medium exchange steps.”

InSphero will begin delivering microtissues in the GravityTRAP™ 384 format throughout the year, starting with human liver microtissues for early stage drug-induced liver injury (DILI) screening, and multicellular tumor spheroid (MCTS) co-culture models that recreate complex tumor microenvironments for cancer drug screening. In addition to providing assay-ready models in 96- and 384-well formats, Dr. Lichtenberg said that InSphero will offer contract model development services to screening groups that need custom microtissues for specific 384-well projects. “We can assist research teams by doing the 3D model development for them. Our scientific staff is highly experienced in evaluating which cell types readily form microtissues, and they can efficiently create simple, monoculture 3D models, for example from modified tumor cell lines, as well as more complex co-culture models. Our goal is to not only relieve the microtissue and assay development burden, but also long-term sourcing, production and QC costs.”

For more information about InSphero, visit www.insphero.com.

 

InSphero contacts

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jan Lichtenberg
Chief Executive Officer and Co-founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of organotypic 3D cell culture models. The company’s patented technologies include the 3D Select™ Process (pending) and scaffold-free 3D cell culture plates that enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, and tumors. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictive power at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and and LinkedIn, and visit www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

Images

 GravityTrap 384 Microtissue Platform

Image caption:

The GravityTRAP™ 384 Microtissue Platform enables reproducible production, culture, and high-content imaging of InSphero 3D microtissues in a high-throughput compatible format.

 

GravityTRAP 384 Microtissue Platform

Image caption:

The GravityTRAP™ 384 Microtissue Platform contains distinct microtissue culture and media chambers, separated by a unique SureXchange™ pipetting ledge that prevents accidental microtissue loss during aspiration and medium exchange.

 

 

InSphero Holiday Hours

Happy Holidays from InSphero!
We're looking forward to working with you in 2017

 

Holiday Office Hours

InSphero offices will be closed December 24, 2016 through January 2, 2017.  Any inquiries or orders placed during our holiday break will be processed on Tuesday, January 3.

XMas2016 01 002
 

 

 

Microtissues Production Schedule

 

January Microtissue Production Schedule

To help you plan ahead, here's our January production schedule. For more details, please see our Microtissue Production Schedule.

Order by date ► ships on date to US | EU

3D InSight Human Liver Microtissues

Jan 03 ► Jan 10 | Jan 11

Jan 10 ► Jan 17 | Jan 18

Jan 17 ► Jan 24 | Jan 25

Jan 24 ► Jan 31 | Feb 01

 

3D InSight™ Human Islet Microtissues

Jan 17 ► Jan 24 | Jan 25

 

 

 

InSphero Scientist Receives 3Rs Award for Microtissue-based Body on a Chip System

InSphero Scientist Receives 3Rs Award for Microtissue-based Body on a Chip System

Dr. Olivier Frey honored by IQ Consortium and AAALAC International for work on microphysiological system to reduce animal-based drug testing. PDF Version

Schlieren, Switzerland - November 3, 2016 – Dr. Olivier Frey of InSphero AG has received the 2016 IQ Consortium and AAALAC International Global 3Rs Award for Europe, recognizing his pioneering work to integrate advanced 3D microtissue models into microphysiological systems (MPS) for in vitro drug testing. The award was presented to Dr. Frey at the AAALAC International Luncheon, held Wednesday, November 2 in conjunction with the American Association for Laboratory Animal Science (AALAS) 67th National Meeting in Charlotte, North Carolina. 

The Global 3Rs Awards recognize significant innovative contributions toward the advancement of ethical science through the 3Rs of animal research: refinement, replacement, or reduction of animal use. The award selection committee acknowledged Frey’s work to advance MPS technology by interconnecting 3D microtissues derived from human tissues such as liver, heart, endocrine pancreas, or tumor using microfluidic channels to mimic a so-called “Body on a Chip” or BoC. Such systems serve as complex in vitro models used to assess the efficacy or toxicity of a drug in a multi-organ, animal-free system. Frey headed the research, conducted at the ETH Zurich and in collaboration with partners including InSphero, as part of the European Commission EU Body on a Chip (BoC) Project. The award specifically referenced work published in July of 2015 in the Journal of Biotechnology entitled “3D spherical microtissues and microfluidic technology for multi-tissue experiments and analysis,” one of several peer-reviewed publications resulting from the project since 2014.

Dr. Frey, who recently joined InSphero to serve as Microphysiological Systems Product Manager, stated “It is a tremendous honor to receive the 3Rs Award on behalf of all of the scientists who have collaborated on the project since its inception four years ago. As an innovator in the field of 3D cell culture, InSphero was a strong commercial partner and helped keep our work focused on developing a scalable, flexible technology.”

Dr. Jan Lichtenberg, CEO and co-founder of InSphero commented, “We are delighted to have a proven leader in microphysiological systems such as Olivier join the InSphero team. His expertise and familiarity with our advanced 3D tissue models will help us accelerate commercialization of the technology, focusing on pharmaceutical and chemical industry applications that reduce both drug development costs and the need for animal testing.”

For more information about InSphero, visit www.insphero.com.

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jan Lichtenberg
Chief Executive Officer and Co-founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of organotypic 3D cell culture models. The company’s patented technologies include the 3D Select™ Process (pending) and scaffold-free 3D cell culture plates that enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain, and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictive power at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and and LinkedIn, and visit www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

Images

 Frey InSphero Portrait web

Dr. Olivier Frey, recipient of the 2016 IQ Consortium and AAALAC International Global 3Rs Award for Europe. Frey currently serves as Microphysiological Systems Product Manager at Schlieren, Switzerland based InSphero AG.

News Archive

 

Company video

company-video-inspheor